$MPLT

Hanson Kristopher sold $608K of MPLT

Hanson Kristopher (General Counsel) sold 16,508 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $36.82 ($36.00–$37.96, $0.61M total) across 7 trades over 2026-07-15 to 2026-07-17.

Original reporting
SEC EDGAR · Hanson Kristopher
Published Jul 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 5:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may influence sentiment, but it does not change MPLT’s fundamentals or guidance in the text provided.

02

Market read

Traders get a fresh datapoint on insider activity, but there is no accompanying corporate event or new performance information.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-scheduled personal liquidity needs; the filing alone does not establish intent or future selling.

Relevance 5/10Novelty 4/10Timing: filed 2026-07-17, covering sales executed 2026-07-15 to 2026-07-17

Background

This is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc., reported by the General Counsel.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight Therapeutics insider Hanson Kristopher sold about $607.9K of MPLT shares in multiple open-market trades from 2026-07-15 to 2026-07-17.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new company fundamentals emerge.

Evidence & confidence

Form 4 discloses transaction size and timing, but it does not provide new operational, regulatory, or financial information; insider sales often have non-informational motives.

Market effects

Minimal, as this is company-specific insider selling without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted by some traders as more discretionary selling, potentially increasing short-term bearish read-through.

Key entities

  • MapLight Therapeutics, Inc.

    Company whose insider sale is disclosed via Form 4.

  • Hanson Kristopher

    General Counsel who sold 16,508 shares of MPLT for about $607,870.

Related articles

$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

Med

MapLight Therapeutics stock crashes on Phase II schizophrenia data

MapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.

$MPLTMed

MapLight Reports Mixed Results From Phase 2 ZEPHYR Schizophrenia Trial; Shares Fall

MapLight Therapeutics (MPLT) reported mixed topline Phase 2 ZEPHYR schizophrenia results. The 210/3 mg twice-daily dose met the primary PANSS improvement endpoint (effect size 0.37 mITT, p=0.002; 0.50 completers, p=0.002). The 330/6 mg once-daily arm was not statistically significant. Company said cognition improved in impaired patients (effect size 0.51, p=0.041). Shares fell.

$MPLTHighAI 8/10

MapLight Therapeutics stock tumbles 40% on trial results By Investing.com

MapLight Therapeutics (NASDAQ:MPLT) shares fell about 40% after topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. The 210/3 mg twice-daily dose met the primary PANSS endpoint at Week 5 versus placebo, while the 330/6 mg once-daily dose did not. The twice-daily arm also showed significant secondary endpoints; safety was generally tolerable. The company plans an FDA End-of-Phase 2 meeting.

$MPLTMed

MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents

MapLight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism. The study of 161 patients did not meet its primary endpoint: caregiver-reported ABI Social Communication Domain change at week 12 vs placebo. In a prespecified adolescent (12–17) subgroup with baseline irritability, ML-004 improved ABC-I irritability (effect size 1.33, nominal p=0.013) and CGI-I (effect size 1.08, nominal p=0.036). The drug was well tolerated. The company plans an FDA End-of-Phase 2 meeting.